Entinostat (MS-275, SNDX-275): Selective Oral HDAC1/3 Inhibitor in Cancer Research

Executive Summary: Entinostat (MS-275, SNDX-275) is a potent, orally available inhibitor of class I histone deacetylases (HDAC1, HDAC3, and HDAC8), showing strong selectivity and nanomolar-to-micromolar IC₅₀ values in biochemical assays (APExBIO, product page). In vitro, Entinostat induces G1 cell cycle arrest and promotes apoptosis in a broad range of cancer cell lines, including breast, colon, and leukemia models (Schwartz 2022, DOI). In vivo studies report acetyl-histone upregulation and reduced tumor burden in retinoblastoma models. Clinical phase I studies have established its safety profile in combination therapies for advanced solid tumors. Entinostat supports translational oncology by enabling targeted epigenetic modulation of oncogenic and tumor suppressor pathways.

Biological Rationale

Histone deacetylases (HDACs) are enzymes that remove acetyl groups from lysine residues on histone and non-histone proteins. This leads to chromatin compaction and transcriptional repression. Aberrant HDAC activity is implicated in oncogenesis through silencing of tumor suppressor genes and deregulation of cell cycle checkpoints. Class I HDACs, including HDAC1 and HDAC3, have been identified as critical drivers in diverse cancers, making them attractive targets for therapeutic intervention (Schwartz 2022). Selective HDAC inhibitors like Entinostat offer the potential for precise reactivation of silenced genes and restoration of normal cellular homeostasis.

Mechanism of Action of Entinostat (MS-275, SNDX-275)

Entinostat is a synthetic benzamide derivative that inhibits class I HDACs via direct binding to the active site zinc ion. It demonstrates IC₅₀ values of 0.368 μM for HDAC1, 0.501 μM for HDAC3, and 63.4 μM for HDAC8 under standard in vitro conditions (pH 7.4, 37°C) (APExBIO). This selective inhibition increases histone acetylation, resulting in a more relaxed chromatin structure and enhanced transcriptional activation of genes involved in cell cycle arrest and apoptosis. Entinostat’s effects extend to non-histone proteins, modulating pathways such as p21^Cip1/Waf1 induction and caspase-3/7-mediated apoptosis (Schwartz 2022).

Evidence & Benchmarks

• Entinostat inhibits HDAC1 (IC₅₀ = 0.368 μM) and HDAC3 (IC₅₀ = 0.501 μM) in biochemical assays at 37°C and pH 7.4 (APExBIO).
• Induces G1 cell cycle arrest and apoptosis (caspase 3/7 activation) in breast, lung, myeloma, and colon cancer cell lines (Schwartz 2022, DOI).
• Reduces tumor burden and increases acetyl-histone levels in murine and rat retinoblastoma models following systemic administration (Entinostat 5–10 mg/kg, 2–4 weeks) (APExBIO).
• Demonstrates cytotoxicity via increased reactive oxygen species and apoptosis in solid tumor studies (Schwartz 2022).
• Phase I trials (Entinostat + 13-cis retinoic acid) report tolerable safety and defined recommended phase II dosing in advanced solid tumors (Schwartz 2022).

For extended data on performance in translational oncology, see our related article here, which provides atomic, verifiable facts on mechanism and workflow integration. This article expands on those findings with in-depth storage, solubility, and workflow optimization parameters.

Applications, Limits & Misconceptions

Entinostat is utilized in oncology research for:

• Epigenetic modulation studies targeting tumor suppressor gene reactivation.
• In vitro anti-proliferative and pro-apoptotic screening in solid and hematologic malignancies.
• Preclinical evaluation of chemosensitization in combination regimens.
• In vivo models of retinoblastoma and other tumor types for mechanism-oriented research.

For workflow guidance and troubleshooting, see Entinostat (MS-275): HDAC1/3 Inhibition in Cancer Research, which offers practical advice for maximizing data fidelity in cellular and animal studies. This current article augments that resource with updated dosing, storage, and clinical translation evidence.

Common Pitfalls or Misconceptions

• Water solubility is poor; Entinostat requires DMSO (≥18.8 mg/mL) or ethanol (≥7.4 mg/mL with ultrasonication) for stock solutions. Direct aqueous dissolution is ineffective (APExBIO).
• Entinostat is not a pan-HDAC inhibitor; selectivity is high for class I HDACs and minimal for HDAC8 at commonly used concentrations.
• Long-term storage of Entinostat solutions (even at -20°C) can lead to degradation; only solid forms are stable for several months.
• Not all tumor types are equally sensitive; efficacy in non-malignant cells or certain resistant cancer subtypes is limited (Schwartz 2022).
• Clinical efficacy is not established as a monotherapy; most clinical trials use Entinostat in combination with agents like retinoic acid.

For a mechanistic deep dive contrasting these limitations, see Entinostat (MS-275, SNDX-275): Mechanistic Depth and Strategy, which this article updates with recent clinical-phase and benchmarking data.

Workflow Integration & Parameters

For optimal use in research and preclinical settings:

• Prepare stock solutions in DMSO or ethanol, warming to 37°C and using ultrasonic agitation for complete solubilization.
• Store solid Entinostat at -20°C; ship on blue ice to maintain integrity (APExBIO A8171).
• Avoid extended storage of prepared solutions; make fresh aliquots for each experimental cycle.
• Use validated concentrations in cell-based assays (0.1–10 μM) and in vivo studies (5–10 mg/kg), adjusting for solvent compatibility and toxicity.
• Monitor acetyl-histone levels and cell cycle/apoptosis markers to confirm target engagement.

For advanced workflow integration—including troubleshooting and comparative HDACi analyses—refer to Strategic Epigenetic Modulation in Oncology: Mechanistic Applications. This resource complements the procedural focus here with broader strategic context.

Conclusion & Outlook

Entinostat (MS-275, SNDX-275), as supplied by APExBIO, is a rigorously characterized, selective class I HDAC inhibitor pivotal for both mechanistic and translational oncology research. Its well-defined biochemical selectivity, validated anti-proliferative effects, and compatibility with in vitro and in vivo workflows make it a leading tool for epigenetic modulation and preclinical drug evaluation. Ongoing clinical studies will further clarify its therapeutic scope, particularly in combination regimens targeting solid tumors. Implementation of validated protocols and recognition of compound-specific limits are essential for data reproducibility and translational success.